Core Viewpoint - The company has obtained a drug production license for lactulose active pharmaceutical ingredient, marking a significant milestone in its strategic expansion into the raw material and health sectors [1][2]. Group 1: License Details - The drug production license was issued by the Shandong Provincial Drug Administration, with the license number Lu20250024, valid until October 28, 2030 [1]. - The production facility is located in the Yucheng High-tech Industrial Development Zone, Shandong Province, and is authorized to produce lactulose solution for registered use only [1]. Group 2: Impact on the Company - The acquisition of the drug production license accelerates the application, registration, and market launch processes for lactulose, initiating the company's diversification into raw materials [2]. - This milestone is seen as a key leverage point for enhancing industry value and strengthening market competitiveness, aligning with the company's goal to establish itself as a world-class provider of functional and health solutions [2]. - Currently, lactulose is only exported to select overseas markets, but future approvals in domestic and major global markets are expected to boost sales revenue and operational performance, although the immediate impact on current performance is anticipated to be minimal [2].

Core Viewpoint - The company, Baolingbao (002286.SZ), has obtained a Drug Manufacturing License from the Shandong Provincial Drug Administration, which accelerates the application, registration, and market launch process for its first active pharmaceutical ingredient, lactulose, marking the beginning of the company's diversification in raw materials [1] Group 1 - The acquisition of the Drug Manufacturing License is a significant regulatory milestone for the company [1] - The approval facilitates the subsequent steps for the company's first raw material drug, lactulose [1] - This development represents the start of the company's strategy to diversify its raw material offerings [1]